Roche
Coverage of Roche in the Nexus archive.
- They left McKinsey to help businesses fight patent violations. See the pitch deck they used to raise $10 million.
Stilta, a startup using AI-powered software to help businesses combat patent violations, raised $10.5 million in seed funding. Founded by four former McKinsey colleagues, the company's investors include Andreessen Horowitz, Y Combinator, and employees from AI companies like OpenAI.
- STAT+: Roche drug sets new standard for KRAS-driven lung cancer
Roche's drug establishes a new standard for treating KRAS-driven lung cancer. The article is part of a biotech newsletter discussing recent developments in the sector, including FDA regulatory updates and political changes affecting biopharma policy.
- Roche selects Hyderabad to set up digital tech hub
Roche, a Swiss healthcare company, is establishing a digital tech hub in Hyderabad, expanding its existing global tech hub network in India, which currently includes Pune.
- STAT+: Sanofi names new R&D head as it tries to jumpstart pipeline
Sanofi appointed Paulo Fontoura as global head of R&D to rejuvenate its pipeline under new CEO Belén Garijo. Fontoura, a neurologist with prior roles at Xaira Therapeutics and Roche, replaces Houman Ashrafian, who is leaving for an external opportunity.
- Roche’s global survey highlights urgent need to shift diabetes care from disease treatment to mental wellbeing
Roche’s global survey emphasizes the need to prioritize mental wellbeing in diabetes care, as nearly one in ten people in Hong Kong live with diabetes. The city faces a growing public-health challenge due to an ageing population, shifting lifestyles, and a high number of undiagnosed cases.
- Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
Roche is entering a $2.3 billion deal with Nurix Therapeutics to develop bexobrutideg, an oral BTK degrader. Nurix receives $700 million upfront for co-developing the drug targeting chronic lymphocytic leukemia and other diseases.
- STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
The FDA is reviewing a drug approval program initiated by former commissioner Marty Makary after receiving mixed feedback, and has launched a safety study of the mifepristone abortion pill, potentially leading to distribution restrictions under the Trump administration. Antiabortion groups and Republican lawmakers supported the study, which is expected to take six months.
- STAT+: Hims’ sales miss as telehealth competition grows
Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.
- STAT+: Roche to buy PathAI for $750 million
Roche has signed a deal to acquire PathAI for $750 million upfront, with potential additional earnings of $300 million. The acquisition aims to accelerate Roche's use of artificial intelligence in pathology diagnostics. The agreement is expected to close in the second half of the year.